StockNews.AI
TMDX
StockNews.AI
215 days

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TransMedics Group, Inc. - TMDX

1. Pomerantz LLP investigates TransMedics for potential securities fraud claims. 2. Scorpion Capital's report alleges fraudulent billing and misuse of medical devices. 3. Ongoing regulatory scrutiny includes investigations by DOJ and IRS into Medicare fraud. 4. TransMedics faced customer dissatisfaction, with some centers discontinuing device use. 5. Stock price dropped 5.16% after the report, indicating investor concerns.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Allegations of fraud have significantly harmed TMDX's stock price. Past examples show that similar allegations led to steep declines in biotech stocks.

How important is it?

The investigation and allegations relate directly to TMDX’s operational integrity and market confidence. Such issues are critical for stock valuation and performance.

Why Short Term?

Immediate investor reaction has resulted in a significant drop in stock price. Ongoing investigations could continue to threaten TMDX’s market position quickly.

Related Companies

TMDXSCOR
Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether TransMedics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class]On January 10, 2025, Scorpion Capital ("Scorpion") published a report on TransMedics' business practices, which allegedly include fraudulent billing schemes, off-label misuse of its devices, and reliance on kickbacks to drive sales. The Scorpion report also describes ongoing regulatory scrutiny of TransMedics, reporting investigations by the U.S. Department of Justice, the Internal Revenue Service, and state attorneys general into Medicare fraud linked to organ acquisition costs. The Scorpion report also describes alleged customer dissatisfaction, asserting that prominent transplant centers have discontinued their use of TransMedics devices, citing concerns over their clinical value.On this news, TransMedics' stock price fell $3.74 per share, or 5.16%, to close at $68.81 per share on January 10, 2025.Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.Attorney advertising. Prior results do not guarantee similar outcomes.SOURCE: Pomerantz LLP

Related News